Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Amide containing NBTI antibacterials with reduced hERG inhibition, retained antimicrobial activity against gram-positive bacteria and in vivo efficacy
ID
Kokot, Maja
(
Author
),
ID
Weiss, Matjaž
(
Author
),
ID
Zdovc, Irena
(
Author
),
ID
Šenerović, Lidija
(
Author
),
ID
Radakovic, Natasa
(
Author
),
ID
Anderluh, Marko
(
Author
),
ID
Minovski, Nikola
(
Author
),
ID
Hrast, Martina
(
Author
)
PDF - Presentation file,
Download
(3,61 MB)
MD5: 6FC6ED9BBB3E77C73C3AC851DC40CF97
URL - Source URL, Visit
https://www.sciencedirect.com/science/article/pii/S0223523423000752
Image galllery
Abstract
Novel bacterial topoisomerase inhibitors (NBTIs) are new promising antimicrobials for the treatment of multidrug-resistant bacterial infections. In recent years, many new NBTIs have been discovered, however most of them struggle with the same issue - the balance between antibacterial activity and hERG-related toxicity. We started a new campaign by optimizing the previous series of NBTIs, followed by the design and synthesis of a new, amide-containing focused NBTI library to reduce hERG inhibition and maintain antibacterial activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). This optimization strategy yielded the lead compound 12 that exhibits potent antibacterial activity against Gram-positive bacteria, reduced hERG inhibition, no cardiotoxicity in zebrafish model, and a favorable in vivo efficacy in a neutropenic murine thigh infection model of MRSA infection.
Language:
English
Keywords:
NBTIs
,
DNA gyrase
,
topoisomerase IV
,
antibacterials
,
MRSA
,
hERG inhibition
,
in vivo efficacy
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
FFA - Faculty of Pharmacy
VF - Veterinary Faculty
Publication status:
Published
Publication version:
Version of Record
Year:
2023
Number of pages:
13 str.
Numbering:
Vol. 250, art. 115160
PID:
20.500.12556/RUL-144295
UDC:
615.28
ISSN on article:
0223-5234
DOI:
10.1016/j.ejmech.2023.115160
COBISS.SI-ID:
141418755
Publication date in RUL:
13.02.2023
Views:
781
Downloads:
107
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
European journal of medicinal chemistry
Shortened title:
Eur. j. med. chem.
Publisher:
Elsevier
ISSN:
0223-5234
COBISS.SI-ID:
25429760
Licences
License:
CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:
http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:
The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Secondary language
Language:
Slovenian
Keywords:
DNA giraza
,
topoizomeraza IV
,
antibakterijska zdravila
,
inhibicija
,
učinkovitost in vivo
,
farmacevtska kemija
,
bakterije
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0017
Name:
Modeliranje kemijskih procesov in lastnosti spojin
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0208
Name:
Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin
Funder:
ARRS - Slovenian Research Agency
Funding programme:
Young researchers
Project number:
39010
Funder:
ARRS - Slovenian Research Agency
Funding programme:
Young researchers
Funder:
Other - Other funder or multiple funders
Funding programme:
National Institute of Chemistry, Proof of Concept NICKI
Funder:
Other - Other funder or multiple funders
Funding programme:
University of Ljubljana Innovation Fund
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back